Drug Trial Radar · NCT05150691
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
796
Planned (sponsor's estimate)
Start
Jan 31, 2022
Primary completion
Aug 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- DualityBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Dec 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Conditions
- HER2-positive Advanced Solid Tumor
Interventions
DB-1303/BNT323Biological
Administered IV
Pertuzumab InjectionDrug
Administered IV
RitonavirDrug
Administered oral
ItraconazoleDrug
Administered oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by CTCAE v5.0.Time frame: up to 21 days after C1D1
- Phase 1: Percentage of participants with AEs in Part 1 graded according to NCI CTCAE v5.0Time frame: Up to Safety Follow-Up visit, approximately 35 days post-treatment
- Phase 1: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 1: Maximum Tolerated Dose (MTD) of DB-1303Time frame: Up to Safety Follow-Up visit, approximately 35 days post-treatment
- Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1303Time frame: Up to Safety Follow-Up visit, approximately 35 days post-treatment
- Percentage of participants with AEs in Part 2 graded according to NCI CTCAE v5.0Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 2: Percentage participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 2: Percentage of Objective Response Rate (ORR) as assessed by RECIST 1.1.Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 2 (Dose Expansion 10 only): To evaluate the effect of ritonavir on DB-1303 and P1003 PK in subjects with HER2-expressing, HER2-amplified, or HER2-mutated advanced solid malignant tumorsTime frame: up to safety follow-up visit, approx. 35 days post-treatment
- Phase 2 (Dose Expansion 10 only): To evaluate the effect of itraconazole on DB-1303 and P1003 PK in subjects with HER2-expressing, HER2-amplified, or HER2-mutated advanced solid malignant tumors.Time frame: up to safety follow-up visit, approx. 35 days post-treatment
Locations
102 sites in 6 countries. Site status is shown where the registry gives one.
Helios Clinical Research
Cerritos, California · Active not recruiting
California Research Institute
Los Angeles, California · Active not recruiting
Sharp Memorial Hospital
San Diego, California · Active not recruiting
Washington Cancer Institute at MedStar Washington Hospital Center
Washington D.C., District of Columbia · Active not recruiting
Advanced Research LLC
Coral Springs, Florida · Active not recruiting
The Oncology Institute of Hope and Innovation
Lakeland, Florida · Active not recruiting
D&H Cancer Research Center LLC
Margate, Florida · Active not recruiting
HCA Mercy Hospital
Miami, Florida · Withdrawn
BRCR Medical Center Inc.
Plantation, Florida · Active not recruiting
BRCR Medical Center Inc.
Tamarac, Florida · Active not recruiting
Southeastern Regional Medical Center, LLC
Newnan, Georgia · Active not recruiting
Kapi'olani Medical Center for Women and Children
Honolulu, Hawaii · Active not recruiting
University of Chicago
Chicago, Illinois · Active not recruiting
Women's Cancer Care
Covington, Louisiana · Withdrawn
Holy Cross Hospital
Silver Spring, Maryland · Withdrawn
Massachusetts General Hospital
Boston, Massachusetts · Active not recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Active not recruiting
Profound Research LLC/Michigan Hematology & Oncology Consultants
Dearborn, Michigan · Withdrawn
David C. Pratt Cancer Center
St Louis, Missouri · Active not recruiting
Women's Cancer Center of Nevada
Las Vegas, Nevada · Withdrawn
Northwell Health
Lake Success, New York · Withdrawn
Laura & Isaac Perlmutter Cancer Center at NYC Langone Health
New York, New York · Active not recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Active not recruiting
North Shore Hematology Oncology Associate P.C. DBA New York Cancer and Blood Specialists
Shirley, New York · Active not recruiting
Regional Medical Oncology Center
Wilson, North Carolina · Withdrawn
Gabrail Cancer Center
Canton, Ohio · Active not recruiting
University of Oklahoma
Oklahoma City, Oklahoma · Active not recruiting
Rittenhouse Hematology Oncology
Philadelphia, Pennsylvania · Withdrawn
Thomas Jefferson University
Philadelphia, Pennsylvania · Active not recruiting
AHN West Penn Hospital
Pittsburgh, Pennsylvania · Active not recruiting
Tennessee Oncology
Nashville, Tennessee · Active not recruiting
Clinical Trial Network
Houston, Texas · Withdrawn
Oncology and Hematology of South Texas, PA
Laredo, Texas · Active not recruiting
NEXT Virginia
Fairfax, Virginia · Active not recruiting
Swedish Cancer Institute
Seattle, Washington · Active not recruiting
Scientia Clinical Research LTD
Randwick, New South Wales, Australia · Active not recruiting
Macquarie Clinical Trials Unit
Sydney, New South Wales, Australia · Active not recruiting
Integrated Clinical Oncology Network Pty Ltd (Icon)
South Brisbane, Queensland, Australia · Active not recruiting
Monash Health
Melbourne, Victoria, Australia · Active not recruiting
The first affiliated hospital of Bengbu medical college
Bengbu, Anhui, China · Recruiting
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.